Anderson–Fabry Disease: From Endothelial Dysfunction to Emerging Therapies
The Anderson–Fabry disease is a rare, X-linked, multisystemic, progressive lysosomal storage disease caused by α-galactosidase A total or partial deficiency. The resulting syndrome is mainly characterized by early-onset autonomic neuropathy and life-threatening multiorgan involvement, including rena...
Saved in:
Main Authors: | Cosimo A. Stamerra, Rita Del Pinto, Paolo di Giosia, Claudio Ferri, Amirhossein Sahebkar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Advances in Pharmacological and Pharmaceutical Sciences |
Online Access: | http://dx.doi.org/10.1155/2021/5548445 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anderson–Fabry Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification, and Therapeutic Strategies
by: Chiara Tognola, et al.
Published: (2025-01-01) -
The vestibular and oculomotor dysfunction in Fabry disease: a cohort study in China
by: Yinglin Leng, et al.
Published: (2025-12-01) -
Fabry Disease and Early Stroke
by: U. Feldt-Rasmussen
Published: (2011-01-01) -
The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease
by: Mónica Furlano, et al.
Published: (2022-01-01) -
Faber’s Maple: Acer fabri
by: Gary W. Knox
Published: (2014-02-01)